Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Breast 3Lymphoid 2Gynecologic 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1COVID-19 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Atorvastatin × Lymphoid × Clear all
NCT04904536 2025-04-10

STRONGER

The George Institute

Phase 3 Active not recruiting
190 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Neurologic Manifestations

NCT03066466 2021-04-27

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

Loyola University

Phase 3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡